CTI is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. Our mission is to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers.
Our priority and sense of purpose is —the PATIENT. CTI’s patient focus shapes our culture, organization and values.
Company success is dependent on our EMPLOYEES’ creativity and dedication. Without this talent, commitment and focus, we would not reach the ambitious goals we set for ourselves.
Our employees are dedicated to TEAMWORK. We have a true sense of ownership for our work and how it is tied directly to products that may significantly improve the outcome of patients’ lives.
We feel a responsibility to give back to our COMMUNITY. We contribute to numerous local organizations and support employee initiatives beyond the workplace.
The “patient first” focus gives us a greater understanding of our market—it is the key to serving our customers well and building SHAREHOLDER value.
Next Generation Pipeline
Our product pipeline includes next generation drug candidates for some of the leading classes of cancer treatments.